Triphala Kwath and Trikatu Capsules in the management of Dyslipidemia/Medoroga.

A Comparative Pre clinical and Clinical Efficacy studies of Triphala Kwath and Trikatu Capsules in the management of Medoroga w.s.r to Dyslipidemia and Associated complications.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/09/021366

Enrollment

Registered

2019-09-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

Intervention1: Triphala kwath and Trikatu capsules: Triphla kwath 20ml bid with one table spoon honey Route of administration - Orally Duration- 60 days Trikatu capsules 500mg bid Route of administra

Eligibility

Inclusion criteria

Inclusion criteria: a) Diagnosed and confirmed cases of dyslipidemia on the basis of investigations. b) Patient between the age group of 40-60 years of either sex who will fulfill the criteria of objective and subjective parameters.

Exclusion criteria

Exclusion criteria: a) Patient not willing for the trial. b) All Medo Rogi presenting with complication like Prameha Pidika. c) Drug induced. d) Patients having illness like TB, carcinoma, renal and liver disorders. e) Patient having past history of MI and unstable angina. f) Uncontrolled dyslipidemia. g) Patient below 40 years and above 60years of age.

Design outcomes

Primary

Measure	Time frame
All cause mortalityTimepoint: 5 years	—

Secondary

Measure	Time frame
HospitalizationTimepoint: 10 yrs follow up	—

Countries

India

Contacts

Public ContactDr Anjli Sharma

RGGPG Ayurvedic college And Hospital Paprola distt kangra

dranjana269@gmail.com7018101789

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026